Among the wide variety of diagnostic and therapeutic challenges in the clinical workplace, infectious diseases pose unusually difficult problems. First, the diversity of disease-causing agents is prodigious, and infectious agents may disseminate to and invade almost any host anatomic compartment. Second, these agents, because of their short generation times and, in some cases, high mutation rates, evolve quickly, resulting in evasion of host defenses, inter-and intrahost diversification in real time, and acquired resistance to antimicrobial drugs. Third, some infectious diseases progress quickly, i.e., within hours or days, and offer only a fleeting, narrow window of opportunity for successful therapeutic intervention early in the course of disease. Thus, to be actionable, diagnostic tests must be broad in their range, specific, sensitive, and rapid. These needs have not been adequately met by current, routine approaches, such as cultivation, serology, and specific PCR assays. As a result, inappropriately broad or mistargeted antimicrobial agents are used, resulting in drug resistance and other adverse effects, and important diseases are untreated or treated too late. A recently published case report by Wilson et al. (1 ) highlights the potential impact of DNA sequencing technology on infectious disease diagnosis, and illustrates in a best-case scenario how this technology may address these needs.
The report describes a 14-year-old boy with severe combined immunodeficiency, who had undergone bone marrow transplantation and was maintained on monthly intravenous infusions of immune globulin and antibiotic prophylaxis against Pneumocystis pneumonia. Approximately 1 month after a trip to Puerto Rico, he experienced 10 days of unexplained fever, headache, and conjunctivitis. Over the course of the following 12 months, he suffered from uveitis, thrombocytopenia, and 2 more acute episodes of fever, headache, and photophobia and developed a lymphocytepredominant cerebrospinal fluid (CSF) pleocytosis, as well as biopsy-proven granulomatous leptomeningitis. After continued clinical deterioration, and almost 1 year after the initial onset of this illness, CSF and serum were sent to some of the authors for nucleic acid extraction and shotgun untargeted sequencing of DNA directly from these samples.
Shotgun (or metagenomic) sequencing provides a means of assessing the gene and genomic content of a clinical sample in a relatively unbiased manner, without an a priori requirement for a suspect organism. As the capabilities and efficiencies of DNA sequencing platforms rocket skyward, plummeting costs and exponentially increasing numbers of available sequence reads mean that low-abundance DNA or RNA fragments in a clinical sample become ever more easily detected and characterized.
The issues then for investigators seeking evidence of a microbial agent using this metagenomic approach are whether the agent and its nucleic acids are present in sufficient abundance in the sample relative to those of the host and other background organisms and whether the agent is sufficiently well characterized so as to be recognized based on the available, random reads of its genome sequence. Previous studies have shown that both suspected and unsuspected, as well as previously characterized and uncharacterized, microbial agents can be identified with this approach. Examples include the discovery of a novel arenavirus in liver and kidney transplant tissue (2 ) and genome reconstruction of an epidemic strain of Shiga toxin-producing Escherichia coli found in stool samples (3 ) . Despite the importance of these findings, weeks of laboratory effort were required, and for this and other reasons, the results did not lead to changes in clinical management. Thus, another issue is whether or how a metagenomics approach might be deployed in the clinical workplace, so as to achieve clinical utility.
In the case presented by Wilson et al., the data yielded an unexpected finding only 48 h after initiation of the laboratory investigation-a finding that in this case was actionable. About 3 million sequencing reads were generated from a 750-L sample of CSF that was collected during the boy's third hospitalization 1 year after onset of his illness. An in-house sequence analysis pipeline was used to filter out the large majority of human genome reads and then find similarities to the set of reference microbial genome sequences in the National Center for Biotechnology Information database. Of the roughly 53 000 nonhuman sequence reads, 475 (or 80.6% of the 589 bacterial reads) were identified as fragments of a Leptospira genome. Leptospirosis is a relatively rare bacterial disease in the US (100 -200 cases per year) but is quite common in other regions of the world, including Puerto Rico; it is transmitted by contact with contaminated fresh water. The boy's illness conformed to a well-recognized but relatively rare clinical presentation of this disease. Importantly, leptospirosis generally responds well to penicillin. Thus, as soon as the organism was identified from the CSF sequence analysis, the patient was begun on this antibiotic, and within 7 days he had largely recovered. The diagnosis was subsequently confirmed with traditional targeted tests for leptospirosis.
This case report highlights several important points related to the application of shotgun sequencing for real-time infectious disease diagnosis.
First, in addition to timeliness and high specificity, sequence data, to be of value, must predict the presence of an organism for which treatment is indicated and for which effective treatment is recognized, or at least an organism whose presence is significant for epidemiology or predictions about clinical outcome. Not all sequence data, especially when randomly generated from a pool of mixed, total DNA from a sample, provide reliable taxonomic identification at the necessary level of resolution, e.g., species. And when the sequence is an imperfect match, how close is close enough to infer clinically relevant information? The answer will depend on the degree to which the sequence-based population structure of the relevant organism and the behavior of the members are understood. Further, sequence data may not provide actionable information about drug susceptibility, because, as an example, there are few drug resistance genes whose presence alone is highly correlated with expression of resistance. Detection of specific RNAs may be useful for suggesting that an organism is biologically active and that genes are expressed, but RNAs also do not necessarily predict organismal behavior, such as drug resistance. Given the sequence and clinical data from this case, decisionmaking by Wilson et al. was relatively straightforward because (a) Leptospira santarosai was identified at the species level and is a known pathogen; (b) any Leptospira species can be assumed to be pathogenic for humans and deserving of treatment when found in CSF; (c) the clinical features of the case were consistent with leptospirosis; and (d) penicillin resistance has not been reported in Leptospira spp.
Second, it is sometimes difficult to acquire an appropriate clinical sample from which actionable sequence data about the causative agent can be reliably generated. Even in systemic infections, the agent may be transient and/or present at low abundance in affected anatomic compartments. Many of the most dramatic clinical features of infectious disease are caused by the host immune response to an agent that was present earlier or to the damage it caused, rather than by its ongoing presence. Samples from body sites typically colonized by the indigenous microbiota pose challenges, since these microbiota create a great deal of sequence background against which the true signal of the causative agent must be discerned. Interpretation of this signal is made more challenging because many pathogens colonize human skin and mucosa without necessarily causing disease, and therefore may be present without being clinically significant. Wilson et al. were fortunate that CSF was relevant and available from a phase of this illness characterized by active infection. In addition, the microbial sequence background in CSF is much less complex and less abundant than it is in other sample types.
Finally, what are the key determinants as to whether, how, and when this technology and workflow will become validated resources within most clinical settings? Sequencing technology is already exploited for a variety of clinical applications, including tumor characterization, newborn screening, and viral drug susceptibility testing (4 ) . This means that the instruments and sample processing procedures are increasingly available and familiar to clinical laboratorians and healthcare providers. But in relatively few instances have the challenges of data interpretation and questions about cost-effectiveness been successfully addressed and surmounted. At the present time, routine use of shotgun sequencing for infectious disease diagnosis is not practical.
For several reasons mentioned above, the case described by Wilson et al., despite the relative rarity of the Leptospira sequence reads, was a best-case scenario for sequencing data interpretation and clinical value. Had this been a case of hospital-acquired E. coli pneumonia, the clinical utility of the data from typical samples such as sputum would have been less straightforward, since E. coli can be a common upper-airway colonizer in hospitalized patients. As with human genome sequence data (5 ), we need well-designed studies of clinical utility and cost-effectiveness. With data from such studies in hand, this approach may serve a valuable role in the management of patients with specific clinical syndromes and sample types when multiplexed specific assays fail to provide an answer. Until we have compelling data that show improved clinical outcomes and/or savings in healthcare costs with standardized metagenomic methods, widespread adoption of this approach for infectious diseases will be hard to justify. Yet, with cases like that described by Wilson et 
